ANTI-PROGRAMMED DEATH-LIGAND 1 (PD-L1) ANTIBODIES

Abstract: the present invention provides anti-pd-l1 antigen binding molecules, including antibodies and the antigen binding fragment thereof, and methods for using the same for treating a variety of diseases, including cancers. the antibodies may be delivered to a subject within a pharmaceutical composition for treatment of a variety of diseases, including various types of cancers. administration results in an activated immune system that can then target tumor cells within the subject. additional therapeutic agents, including other pharmaceuticals, may be administered in conjunction with the molecules of the invention to aid the treatment of the subject.

Inventor(s): Xinyan Zhao, Changyun Hu, Yang Lou, Haibin Huang

CPC Classification: C07K16/2827 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250171542